Safety and psychostimulant efficacy of EnXtra® (Alpinia galanga) in healthy adults

This double-blind, randomized, placebo-controlled, parallel group study was conducted to assess the long-term safety and perceivable mental acuity benefits of EnXtra® in healthy individuals.

To do so, 68 healthy individuals were randomized to receive for 12 weeks either EnXtra® (containing 300 mg of Alpinia galanga extract), EnXtra® plus caffeine (200 mg), or a placebo. Outcome measures evaluated were the cardiovascular safety, and the change in perceived alertness and calmness by Bond and Lader mood scales, sleep disturbance by Pittsburgh sleep quality Index and daytime sleepiness by Epworth sleepiness scale of senior fitness test, exercise stress test on bicycle ergometer, hand-grip, and body composition.

Results showed that none of the study group showed any significant change in the ECG or haemodynamic parameters as compared to baseline (p > 0.05). Post consumption, alertness and calmness scores were significantly increased in the EnXtra®, and EnXtra® plus caffeine group (p < 0.001) as compared to placebo. Daytime sleep scores decreased in the EnXtra® group however change was not significant. Sleep quality remained undisturbed in all three arms.

In conclusion, EnXtra® shows cardiovascular safety on long-term usage and has a psychostimulant in healthy adults.

Srivastava S, Mennemeier M, Chaudhary JA. A Randomized Placebo Controlled Clinical Trial Demonstrating Safety & Efficacy of EnXtra® in Healthy Adults [published online ahead of print, 2020 May 15]. J Am Coll Nutr. 2020;1-13.